Accuracy: Installation of a Second CyberKnife(R) Robotic Radiosurgery System in Vicenza Hospital
11/1/2010 6:57:55 AM
SUNNYVALE, Calif., Nov. 1, 2010 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Vicenza Hospital, Ospedale Civile San Bortolo in Italy, has become the first European hospital to be equipped with two CyberKnife® Robotic Radiosurgery Systems. The second System is expected to begin treating patients before the end of the calendar year.
"The CyberKnife is able to deliver accurate radiosurgical treatments quickly and easily anywhere in the body, making it the ideal treatment option for the growing number of radiosurgery cases. With the installation of a second CyberKnife System, we will be able to meet this increasing demand for precise radiosurgical treatment throughout the body and to treat a wider array of patients, including those who were previously considered inoperable or poor surgical candidates due to old age and associated medical condition, and those who seek an alternative to surgery," said Professor Federico Colombo M.D., Director of the Neurosurgical Department at Vicenza Hospital.
Vicenza Hospital, which is located in the Venetian region of Italy, installed its first CyberKnife System in 2003, the first in Europe, and has been using it mainly to treat arteriovenous malformations (AVM) and benign tumors of the brain such as neuromas and meningiomas. The second system will allow an increased number of patients to receive treatments for both intracranial and extracranial tumors. "To date, Vicenza Hospital has treated more than 2,300 patients with the CyberKnife System and the hospital hopes to double the number of patients that benefit from CyberKnife treatment," added Professor Federico Colombo.
With patient interest in CyberKnife radiosurgery and physician referrals expanding exponentially, the addition of a second system at Vicenza is representative of the growing number of CyberKnife Centers purchasing and installing multiple systems worldwide.
"As the indications that can benefit from CyberKnife radiosurgery continue to evolve, the demand for radiosurgery treatments within an institution exceed the capacity of a single CyberKnife System," said Vittorio Puppo, General Manager of Accuray EIMEA (Europe, India, Middle East, Africa). "Vicenza Hospital's expansion is another example of facilities that desire multiple CyberKnife Systems to manage growing patient demand for treatment of tumors not only intracranially, but in the lung, prostate, pancreas and liver."
About Vicenza Hospital
For more information, please visit http://www.ulssvicenza.it/.
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 206 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical usage, clinical benefits, clinical acceptance, anticipated number of patient treatments and multiple system purchases are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2010 fiscal year which has been filed with the Securities and Exchange Commission on August, 31, 2010. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
SOURCE Accuray Incorporated